Literature DB >> 24619146

[Drug-drug interactions: interactions between xenobiotics].

E Haen1.   

Abstract

Drug-drug interactions (DDI) are a major topic in programs for continuous medical education (CME). Many physicians are afraid of being trapped into charges of malpractice; however, DDI cannot be avoided in many cases. They belong to routine medical practice and it is often impossible to avoid them. Moreover, they do not just occur between drugs but between any kind of foreign substance (xenobiotica), such as food (e.g. grapefruit juice, broccoli, barbecue) as well as legal (e.g. tobacco smoke, caffeine and alcohol) and illegal drugs. Therefore, the medical challenge is not just to avoid any interaction. Instead the physician faces the question of how to proceed with drug treatment in the presence of such interactions. Based on the medical education a physician has to judge first of all whether there is a risk for interactions in the prescription being planned for an individual patient. The classification of interactions proposed in this article (PD1-PD4, PK1-PK3) might help as a sort of check list. For more detailed information the physician can then consult one of the many databases available on the internet, such as PSIAConline (http://www.psiac.de) and MediQ (http://www.mediq.ch). Pharmacokinetic interactions can be easily assessed, monitored and controlled by therapeutic drug monitoring (TDM). Besides these tools it is important to keep in mind that nobody knows everything; even physicians do not know everything. So take pride in asking someone who might help and for this purpose AGATE offers a drug information service AID (http://www.amuep-agate.de). Just good for nothing, without being based on any kind of medical approach are computer programs that judge prescriptions without taking into account a patient's individual peculiarities. In case these types of programs produce red exclamation marks or traffic lights to underline their judgment, they might even work in a contrapuntal way by just eliciting insecurity and fear.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619146     DOI: 10.1007/s00115-013-3935-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  11 in total

1.  QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

Authors:  A SELZER; H W WRAY
Journal:  Circulation       Date:  1964-07       Impact factor: 29.690

Review 2.  Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety.

Authors:  E Haen
Journal:  Pharmacopsychiatry       Date:  2011-09-28       Impact factor: 5.788

3.  [Expanding therapeutic reference ranges using dose-related reference ranges].

Authors:  E Haen; C Greiner; W Bader; M Wittmann
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

Review 4.  [Unwanted effects of psychotropic drugs--selected results from a 10-year multicenter project monitoring drugs in psychiatry].

Authors:  R Grohmann; L G Schmidt; K Antretter; E Rüther
Journal:  Internist (Berl)       Date:  1990-07       Impact factor: 0.743

Review 5.  Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.

Authors:  J Arnt; T Skarsfeldt
Journal:  Neuropsychopharmacology       Date:  1998-02       Impact factor: 7.853

6.  Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect.

Authors:  Avinash G Thombre; Scott M Herbig; Jeffrey A Alderman
Journal:  Pharm Res       Date:  2011-06-15       Impact factor: 4.200

7.  Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.

Authors:  J J Miceli; K D Wilner; R A Hansen; A C Johnson; G Apseloff; N Gerber
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

Review 8.  QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Authors:  Katharina Wenzel-Seifert; Markus Wittmann; Ekkehard Haen
Journal:  Dtsch Arztebl Int       Date:  2011-10-14       Impact factor: 5.594

9.  AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

Authors:  C Hiemke; P Baumann; N Bergemann; A Conca; O Dietmaier; K Egberts; M Fric; M Gerlach; C Greiner; G Gründer; E Haen; U Havemann-Reinecke; E Jaquenoud Sirot; H Kirchherr; G Laux; U C Lutz; T Messer; M J Müller; B Pfuhlmann; B Rambeck; P Riederer; B Schoppek; J Stingl; M Uhr; S Ulrich; R Waschgler; G Zernig
Journal:  Pharmacopsychiatry       Date:  2011-09-27       Impact factor: 5.788

10.  Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

Authors:  D Aarsland; J P Larsen; J L Cummins; K Laake
Journal:  Arch Neurol       Date:  1999-05
View more
  2 in total

Review 1.  Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy.

Authors:  Torsten Kratz; Albert Diefenbacher
Journal:  Dtsch Arztebl Int       Date:  2019-07-22       Impact factor: 5.594

2.  [Antihypertensive drugs in psychiatry : Prescription behavior and potential drug-drug interactions].

Authors:  Katharina Endres; Ernst Schiller; Ekkehard Haen
Journal:  Nervenarzt       Date:  2021-05       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.